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Abstract
L-Serine is required for the synthesis of glycine and D-serine, both of which are NMDA receptor
co-agonists. Although roles for D-serine and glycine have been suggested in schizophrenia, little is
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known about the role of the L-serine synthesizing cascade in schizophrenia or related psychiatric
conditions. Here we report a patient with schizophrenia carrying a balanced chromosomal
translocation with the breakpoints localized to 3q13.12 and 9q21.2. We examined this proband
and her son with schizotypal personality disorder for chromosomal abnormalities, molecular
expression profiles, and serum amino acids. Marked decrease of L-serine and glutamate was
observed in the sera of the patient and her son, compared with those in normal controls.
Interestingly, expression of PSAT1 gene, which is located next to the breakpoint and encodes one
of the enzymes in the L-serine synthesizing cascade, was reduced in both patient and her son.
Direct effect of impaired PSAT1 gene expression on decreased serum L-serine level was strongly
implicated by rat astrocyte experiments. In summary, we propose an idea that PSAT1 may be
implicated in altered serine metabolism and schizophrenia spectrum conditions.
Keywords
schizophrenia; balanced chromosomal translocation; PSAT1; L-serine; D-serine; glycine;
glutamate; expression
Introduction
Disturbance of serine metabolism causes many disorders, including hereditary disorders due
to mutations in the genes that regulate biosynthesis of serine and related amino acids (Jaeken
et al., 1996, Jaeken et al., 1997, de Koning et al., 1998, Pineda et al., 2000, de Koning and
Klomp, 2004, Veiga-da-Cunha et al., 2004, Hart et al., 2007). L-Serine is biosynthesized
from 3-phosphoglycerate, a metabolite of glucose in the brain, and requires three enzymatic
steps catalyzed by 3-phosphohydroxypyruvate dehydrogenase (3-PGDH), phosphoserine
aminotransferase 1 (PSAT1), and lastly phosphoserine phosphatase (PSP) (de Koning and
Klomp, 2004). From L-serine, other bioactive amino acids, such as D-serine and glycine are
generated (de Koning and Klomp, 2004). In a previous report, patients with deficiencies in
any of these enzymes presented early with severe neurological manifestations shortly after
birth, including seizures, microcephaly, and psychomotor retardation, that were either fatal
or required serine supplementation for survival (Jaeken et al., 1996, Jaeken et al., 1997, de
Koning et al., 1998, Pineda et al., 2000, Veiga-da-Cunha et al., 2004, Hart et al., 2007).
Schizophrenia is a major psychiatric disorder in which disturbance of glutamate and D-
serine has been suggested (Hashimoto et al., 2003, Bendikov et al., 2007, Sawa, 2009). D-
serine is an endogenous co-agonist for the NMDA-type glutamate receptor and is believed to
underlie the disease pathophysiology via its action on NMDA receptor (Labrie and Roder,
2010). Furthermore, genes coding for D-serine synthesis and degradation, including serine
racemase, PICK1, D-amino acid oxidase, and G72 have been genetically associated with the
disease (Chumakov et al., 2002, Schumacher et al., 2004, Fujii et al., 2006, Morita et al.,
2007). Although synaptic D-serine is dependent on the de novo biosynthesis of L-serine, a
role for the L-serine biosynthesis cascade in schizophrenia remains to be determined.
Here we report on two individuals carrying a hereditary balanced chromosomal
translocation. The mother was diagnosed with schizophrenia, while her son was diagnosed
with schizotypal personality disorder. Resolving chromosome translocation breakpoints has
proved a successful means to identify susceptibility genes for psychiatric disorders (Muir et
al., 2006). In the present study, this approach suggests a role for the PSAT1 gene in
schizophrenia spectrum conditions, which is strengthened by a decreased expression of
PSAT1 and reduced serum levels of L-serine in both subjects.
Ozeki et al. Page 2
Neurosci Res. Author manuscript; available in PMC 2012 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Methods and Materials
Clinical history and neuropsychological assessment
The Japanese proband, recently deceased, was born with no marked medical history
perinatally or in childhood, and married at 18 years old after graduating from high school.
After the birth of her son (her only child) shortly after marriage, she was diagnosed with
schizophrenia, presenting with delusions and hallucinations, and was hospitalized at age 19.
Despite extensive treatment with neuroleptics, her positive symptoms did not improve
significantly, while her negative symptoms (poverty of thought and thought disorder)
worsened steadily. The Positive and Negative Syndrome Scale (PANSS) score was 106
(positive: 32, negative: 28). Because of her deteriorating mental status, further
neuropsychological tests could not be performed except the verbal fluency assessment in
which she said only one word in each test. Neuropsychological tests were performed in
March 2006. The son completed university with no prior psychiatric history, but has had
persistent poor social functioning. At age 57, he is currently employed as a manual laborer.
He is diagnosed to have schizotypal personality disorder with thought disturbance,
inappropriate affect, peculiar behavior, lack of close friends, and excessive social anxiety.
On the Wechsler Adult Intelligence Scale-Revised (WAIS-R), he scored 115 in global
(FIQ), 110 in visual (VIQ), and 119 in performance (PIQ) intellect. On the Wechsler
Memory Scale-Revised (WMS-R), he scored within normal range for verbal memory (110),
general memory (97), attention and concentration (112), and delayed recall (90), but was
subnormal in visual memory (72). He scored poorly on the Wisconsin Card Sorting Test
(WCST), not being able to complete a single category and could not arrive at the correct
answers even after the test rules were revealed to him. This study was approved by the
Institutional Review Boards of National Center of Neurology and Psychiatry and Chiba
University. The controls were healthy volunteers recruited from hospital staff and their
associates. All subjects were biologically unrelated Japanese. They were interviewed with
the Japanese edition of the mini international neuropsychiatric interview (MINI) (Sheehan et
al., 1998, Otsubo et al., 2005), and those who had a current or past history of psychiatric
treatment were not enrolled in the study. Documented informed consent was obtained from
the participants. We recruited 26 controls (13 male and 13 female) for the establishment of
lymphoblastoid cell lines and real-time RT-PCR analysis for PSAT1 mRNA expression (age:
49.0±15.7). Ten controls were recruited for the establishment of lymphoblastoid cells lines
and real-time RT-PCR analysis for mRNA expression of other genes (age: 61.7±11.3). For
serum amino acid measurement, 16 controls were recruited (male 6 and female 10, age:
66.8±12.9).
Lymphoblastoid cell lines from subjects
Mononuclear cells were isolated from peripheral blood by Ficoll-Paque gradient
centrifugation. Lymphoblastoid cell lines were established by transforming B lymphocytes
by Epstein–Barr virus, and grown in RPMI-1640 supplemented with 10% fetal bovine serum
and penicillin/streptomycin.
Fluorescence in situ hybridization (FISH)
Lymphoblastoid cells were treated with colcemid for 1 h followed by a conventional fixing
procedure. Fixed chromosomes were dropped onto microscope slides and stored for 1 week
prior to use. BAC and FOSMID clones were selected from the UCSC genome browser and
obtained from the Wellcome Trust Sanger Institute. Purified clone DNA labeled with
digoxigenin or biotin was hybridized to metaphase spreads and detected with fluorescent
secondary antibodies. Images were captured on a Zeiss Axioskop 2 fluorescence microscope
by using Digital Scientific SmartCapture 2.1 software.
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Total RNA extraction, cDNA synthesis and quantitative real-time RT-PCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer's
instructions. After DNAse treatment by use of the TURBO DNA-free Kit (Ambion), the
quality and quantity of all RNA samples were checked with NanoDrop (NanoDrop
Technologies). cDNA was synthesized from 1 μg of total RNA by using MultiScribe
Reverse Transcriptase High-Capacity cDNA Reverse Transcript Kits (Applied Biosystems).
Quantitative real-time PCR was performed with TaqMan Gene Expression Assays and ABI
7900HT (Applied Biosystems). Assay IDs for each target were as follows: BBX:
Hs00329131_m1, CCDC54: Hs00540426_s1, CEP78: Hs00397220_m1, GNAQ
Hs00387073_m1, and PSAT1: Hs00253548_m1. Primers and probe for BC036229 gene,
which is located in the breakpoint and encodes a non-coding RNA, were designed as 5’-
gaaagatccacctacgacctaagg-3’ (forward), 5’-atctaccagatgaactcttccatgg-3’ (reverse), and FAM-
caccaatttcaaatccgaaat-MGB (labeled TaqMan probe). PCR conditions were as follows: 95oC
for 2 min, 50 cycles of 95oC for 15 sec, and 60oC for 1 min. The data were presented as
expression level relative to glyceraledehyde-3-phosphate dehydrogenase (GAPDH)
expression.
Primary rat astrocyte culture
Primary rat astrocyte cultures were prepared from cortices of P2 pups of Sprague-Dawley
rats (Charles River Laboratories). Single cell suspensions were obtained by serial trituration
of cerebral cortices with 20G and 26G needles with a 10-ml syringe, followed by the
removal of cell debris with a Cell strainer (BD bioscience). Cells were suspended in NM-15
medium [MEM medium supplemented with L-glutamine, 15% FBS (both from Invitrogen),
6 mg/mL D-glucose (Sigma), and penicillin/streptomycin (Invitrogen)], and seeded on poly-
D-lysine-coated T-75 flasks (Corning) with two brains/flask. Medium was changed on day
3, and every other day thereafter. On day 10-12, the flasks were sealed and shaken at 37°C
overnight. Following an additional shake with D-PBS and complete removal of loosely-
attached cells (oligodendrocytes and microglia), adherent cells (astrocytes) were dissociated
with 0.05% trypsin and collected in NM-15 medium for further use. Typically, we collect
>95% GFAP-positive astrocytes by this method.
RNAi knockdown of PSAT1 in primary rat astrocyte culture
Knockdown of Psat1 gene expression was performed by transfection of Psat1 siRNA or
control siRNA (ON-TARGETplus SMARTpool® siRNA, Dharmacon) by using
Oligofectamine (Invitrogen).
Measurement of amino acids
Amino acids levels were measured by an HPLC system as described previously (Hashimoto
et al., 2005, Yamada et al., 2005). The subject's serum samples were collected between
11AM and noon. Cell culture supernatants were collected 24 h after the last medium change.
Samples were kept frozen at -80°C. The serum levels of glutamate, glutamine, and glycine
were measured using an HPLC system, as reported previously (Hashimoto et al., 2005). D-
and L-Serine were measured with a column-switching HPLC system as reported previously
(Fukushima et al., 2004, Yamada et al., 2005). Briefly, 20 μL of human serum were
homogenized in 180 μl of methanol (HPLC grade). The homogenates were centrifuged at
4500 g for 10 min, and 20 μl of supernatant were evaporated to dryness at 40°C. To the
residue, 20 μL of H2O (HPLC grade), 20 μL of 0.1 M borate buffer (pH 8.0), and 60 μL of
50 mM 4-fluoro-7-nitro-2,1,3-benzoxadiazole (NBD-F; Tokyo Kasei Kogyo Co., Ltd.) in
CH3CN (HPLC grade) were added. The reaction mixture was then heated at 60°C for 1 min,
and immediately supplemented with 100 μL of H2O/CH3CN (90/10) containing 0.1 %
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trifluoroacetic acid (TFA) to quench the reaction. Ten microlitters of the resultant solution
were injected into the HPLC system.
Western blotting
Astrocytes were lysed in RIPA buffer and sonicated. Equal amounts of whole cell lysates
were loaded into each lane of 4-12% NuPAGE Novex Bis-Tris mini gels (Invitrogen).
Electrophoresis, transfer to a polyvinylidene difluoride (PVDF) membrane (Millipore), and
visualization by ECL system was done by a standard method. Rabbit anti-PSAT1 antibody
was a gift from Drs. Do Youn Jun and Young Ho Kim (Korea), and used to detect
endogenous PSAT1 expression.
Statistical analysis
Mann-Whitney U-test was used for the analysis of subject data. L-serine level in astrocyte
culture supernatants were analyzed by Student-t-test.
Results
The proband was known to possess a chromosomal abnormality: however, detailed analysis
on the breakpoint had not been performed. We hypothesized that the uncharacterized
chromosomal abnormality might account for the schizophrenia spectrum diagnoses in both
the proband and her son. In the proband lymphoblastoid cells, FISH localized the
breakpoints to 3q13.12 and 9q21.2 (Fig. 1A and B). On chromosome 3, the breakpoint was
positioned between flanking probes BAC RP11-56M1 and Fosmid G248P86870FB7,
defining its location to a window of approximately 100 kb. This corresponds to the third
intron of 2.7 kb non-coding transcript BC036229. The 5’ end of the BC036229 transcript is
associated with a CpG island that also appears to drive expression of the overlapping, but
shorter transcript LOC100302640 and a transcript with opposite orientation, LOC344595.
The CpG island is poorly conserved among species and the transcripts are all non-coding
and lack non-human orthologs. Therefore, we suggest that these three transcripts are non-
functional transcriptional ‘noise’. On chromosome 9, probe RP11-45D15, spanned the
breakpoint (Fig. 1A). This restricted the breakpoint to approximately 140 kb but the
intensities of the probe on the two derived chromosomes suggested that the breakpoint was
located towards the centromeric end of this window. This places the chromosome 9
breakpoint approximately 100 kb downstream of, and telomeric to, the phosphoserine
aminotransferase 1 gene (PSAT1). Detailed analysis of translocation was performed only in
the proband although the G-banding test identified the similar chromosomal translocation in
her son (data not shown).
In the initial screening of possible molecular changes in these subjects, we measured serum
levels of several amino acids that may play a role in the pathophysiology of schizophrenia
and related disorders (Fig. 1C). Intriguingly, levels of L-serine and glutamate in the subjects
(proband and her son) were significantly lower than normal Japanese controls. In contrast,
we did not observe differences in the levels of glutamine between the subjects and normal
controls. Therefore, we hypothesized that these alterations in the levels of amino acids are
associated with the chromosomal abnormality. While no protein-coding gene is likely to be
disrupted by the breakpoints, we searched for cis-effects of the breakpoints on expression
levels of all the annotated genes with an open reading frame within 500 kb of the
breakpoints in lymphoblastoid cells by quantitative RT-PCR (Fig. 1D). Among the genes
examined, significant and selective decrease in expression was only observed for PSAT1 in
both the proband and her son (Fig. 1D). There were no significant changes in bobby sox
homolog (BBX) and centrosomal protein 78kDa (CEP78) mRNAs, and no mRNA
expression was detected in lymphoblasoid cells for coiled-coil domain containing 54
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(CCDC54) and guanine nucleotide binding protein q polypeptide (GNAQ) genes. To
examine whether decreased PSAT1 expression results in decreased L-serine production by
brain cells, we knocked down PSAT1 by RNAi in rat primary astrocytes in which major
serine signaling takes place in the brain (Fig. 2A). We observed decreased L-serine levels in
supernatants from these astrocyte cultures while we did not see any significant changes in
the levels of other amino acids including D-serine, glutamine, glutamate, and glycine (Fig.
2B).
Discussion
Here we report a case of a proband and her son suffering from schizophrenia spectrum
conditions and carrying a chromosomal translocation. The 9q21 locus where the PSAT1
candidate gene lies adjacent to one of the breakpoints has moderate support for a role in
psychiatric illness from two genome-wide linkage studies (Hovatta et al., 1999, McInnis et
al., 2003). Our data on expression of genes adjacent to the translocation breakpoints
suggested a potential role for PSAT1 in the pathophysiology of their conditions. This is in
line with many previous studies that have shown long-range (up to 1.3 Mb) regional
perturbation of transcription levels by chromosome abnormalities causing illness, even in
the absence of direct gene disruption (Kleinjan and Coutinho, 2009). This phenomenon most
likely results from altered regional chromatin state or separation of up- or down-stream
genomic regulatory elements from the main body of the gene. In agreement with this, and in
contrast to recessive PSAT1 mutations (Hart et al., 2007), we observe only partially reduced
PSAT1 expression and speculate that this mild decrease may be associated with psychiatric
conditions without major developmental deficits. Similar correlations between mutation
allele and severity of phenotype have been reported for many other disease genes including
NPAS3 which can present as a psychiatric diagnosis (Huang et al., 2010), a psychiatric
diagnosis co-morbid with mild mental retardation (Kamnasaran et al., 2003, Pickard et al.,
2005) or severe mental retardation/Sotos syndrome (Visser et al., 2010).
We fully acknowledge various limitations of this study. First, no karyotypically normal
family members were available to act as negative controls in the serum studies or to define
the statistical significance of the co-segregation of chromosomal translocation with illness.
Additionally, no further experimental interventions such as the administration of L- or D-
serine are planned for the surviving son because approval from the ethical committee and
subject is unlikely. Even for the subjects studied, no further clinical information can be
expected although all possible clinical assessment and tissue acquisition approved by the
ethical committee has been completed. Second, the selective downregulation of PSAT1 and
L-serine reasonably suggests a mechanistic link between this chromosomal translocation and
schizophrenia spectrum conditions that are known to associate with disturbed glutamatergic
neurotransmission, but it is impossible to prove the causal link in clinical studies. However,
small pedigree cytogenetic and sporadic copy number findings are proving incredibly
important to the biological description of neuropsychiatric disease processes such as those
responsible for autism and schizophrenia (Gill et al., 2010, Pinto et al., 2010). This paper
seeks to add to this knowledge by provoking further testing of the candidacy of the PSAT1
gene. For example, although beyond the scope of this report, generation of Psat1 knockout
mice and their characterization (especially the heterozygote knockout mice) would provide
us with a more definitive picture of how this gene contributes to brain function and
psychiatric disorders, especially schizophrenia. We do not know the reason for the
discrepancy in the levels of D-serine and glycine between the proband and son, but this may
be a reflection of age, gender, individual genetic background, physiological state or
medication. For these very reasons, the observed statistical differences in metabolites
between carrier and control groups are of greater importance than individual values.
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In addition to reducing L-serine concentrations, deficits in PSAT1 activity may have an
alternative pathological effect through reduction of its direct product, L-Serine-o-phosphate
(L-SOP). L-SOP is a potent agonist of group III metabotropic glutamate receptors in the
brain (Antflick et al., 2009). Through these receptors L-SOP has been shown to modulate
adult neurogenesis in the hippocampus: reducing neural proliferation and promoting
maturation and survival of newly generated neurons (Nakano et al., 2007, Saxe et al., 2007).
One abundant group III metabotropic glutamate receptor stimulated by L-SOP is mGluR7
(Okamoto et al., 1994), encoded by the GRM7 gene. The GRM7 gene has been linked by
several genome-wide association and copy number variation studies to increased risk of
schizophrenia (Walsh et al., 2008), bipolar disorder (WTCCC, 2007, Baum et al., 2008,
Ferreira et al., 2008, Zhang et al., 2009) and attention-deficit hyperactivity disorder (Elia et
al., 2009).
Accumulating evidence suggests therapeutic potentials in the supplementation or
intervention with amino acids to patients with schizophrenia (Buchanan et al., 2007). In
particular, strategies that target glutamatergic neurotransmission have been showing
promising results. These include the supplementation of D-serine, D-cycloserine, D-alanine,
or glycine, as well as the modulation of their transporters (Kantrowitz et al., 2010, Cascella
et al., 1994, Heresco-Levy et al., 2004, Heresco-Levy and Javitt, 2004, Javitt, 2004,
Heresco-Levy et al., 2005, Lane et al., 2005, Lane et al., 2006, Tsai et al., 2006, Javitt,
2008). Although it is not clear from our current data whether L-serine is simply utilized to
synthesize D-serine, they suggest the potential of L-serine supplementation for the treatment
of patients with schizophrenia.
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Figure 1.
Chromosomal translocation and molecular profiles of the proband and her son. A)
Fluorescent in situ hybridization positions the chromosome 9q21.2 breakpoint. A metaphase
spread (left) and interphase nucleus (right) stained with 4',6-diamidino-2-phenylindole
(DAPI) (blue). A green fluorescently labeled probe generated from RP11-45D15 BAC clone
DNA is shown hybridized to the normal chromosome 9 and derived chromosomes 3 and 9
on a metaphase spread (left) stained blue with DAPI. This triple signal, also seen in an
interphase nucleus (right), indicates that the DNA probe sequence spans the breakpoint. The
relative proportions of signals on the two derived chromosomes suggest that the breakpoint
is located towards the centromeric end of the DNA probe sequence. B) Schematic
representation of the two breakpoint loci. The BAC and fosmid clones flanking the
chromosome 3 breakpoint within the BC036229 transcript are shown as black rectangles.
The magnified genomic context of the disruption is shown below including the location and
orientation of nearby genes (nearest genes, grey block arrows: other genes, white block
arrows). The chromosome 9 breakpoint does not directly disrupt a gene but is located close
to PSAT1. The proximity to a segmental duplication pair (the black arrow indicates the
centromeric component and the dashed line indicates the direction of the telomeric
component ~1.8 Mb downstream) may indicate potential chromosome instability in this
region. C) Serum level of L-serine, D-serine, and other relevant amino acids determined by
HPLC. *p=0.013, Mann-Whitney U-test. Control, n=16. The open diamond indicates the
proband. D) mRNA expression of the genes that are adjacent to the breakpoints. Expression
level was determined by quantitative real-time RT-PCR and presented as expression relative
to GAPDH mRNA. PSAT1 mRNA expression level was decreased significantly in the
subjects (proband and her son) (**p=0.0053, Mann-Whitney U-test). No significant
difference was observed for bobby sox homolog (Drosophila) (BBX) and centrosomal
protein 78 kDa (CEP78) mRNA expression. Control: n=26 for PSAT1, n=10 for BBX and
CEP78. The open diamond indicates the proband. mRNA expression of coiled-coil domain
containing 54 (CCDC54), guanine nucleotide binding protein q polypeptide (GNAQ), and
BC036229 was not detected in either subject or control lymphoblastoid cells. See Figure 1B
for the location of each gene.
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Figure 2.
Effects of PSAT1 knockdown by RNAi on L-serine level. A) Successful knockdown of
PSAT1 by siRNA in primary rat astrocytes. Primary rat astrocytes were transfected with
siRNA against PSAT1 or control siRNA. Cells were harvested on day 7 and examined for
PSAT1 protein expression by Western blot analysis by using anti-PSAT1 antibody. GAPDH
expression level was examined for internal control. (-); no transfection. Bar graph shows
PSAT1 expression level relative to GAPDH. B) Amino acids concentration in culture
supernatants of primary rat astrocytes with PSAT1 siRNA. Astrocytes transfected with
either PSAT1 siRNA or control siRNA was determined at 24 h after the last medium change
(day 7 post-transfection) by a high-performance liquid chromatography (HPLC) system.
Error bars represent standard deviation. NT; non-treated, Con; treated with control siRNA,
and Exp; treated with PSAT1 siRNA. **p=0.00175, Student t-test. Data are representative
of three independent experiments.
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